Financial Engines Advisors L.L.C. Makes New $358,000 Investment in Grifols, S.A. (NASDAQ:GRFS)

Financial Engines Advisors L.L.C. purchased a new stake in shares of Grifols, S.A. (NASDAQ:GRFS) during the 4th quarter, Holdings Channel.com reports. The fund purchased 48,136 shares of the biotechnology company’s stock, valued at approximately $358,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. JPMorgan Chase & Co. grew its position in Grifols by 144.0% during the third quarter. JPMorgan Chase & Co. now owns 2,002,511 shares of the biotechnology company’s stock valued at $17,782,000 after buying an additional 1,181,959 shares during the period. Helikon Investments Ltd bought a new position in Grifols in the 4th quarter worth $580,000. Stifel Financial Corp purchased a new position in Grifols during the third quarter valued at $1,043,000. GAMMA Investing LLC increased its position in Grifols by 44.5% in the fourth quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company’s stock worth $37,000 after buying an additional 1,527 shares in the last quarter. Finally, Jane Street Group LLC bought a new position in shares of Grifols in the third quarter worth about $363,000.

Grifols Stock Performance

Shares of NASDAQ GRFS opened at $7.31 on Friday. The stock has a market cap of $5.03 billion, a PE ratio of 6.25 and a beta of 0.35. Grifols, S.A. has a 1 year low of $5.79 and a 1 year high of $9.96. The firm has a fifty day moving average price of $7.56 and a 200-day moving average price of $8.06. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79.

Wall Street Analyst Weigh In

Separately, Morgan Stanley initiated coverage on shares of Grifols in a report on Wednesday, February 12th. They issued an “overweight” rating for the company.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.